Date Title Document
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis Date 04/21/17 Title Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis Download PDF
Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call Date 04/10/17 Title Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call Download PDF
Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite™ Next-Generation Phacoemulsification Platform Date 04/06/17 Title Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite™ Next-Generation Phacoemulsification Platform Download PDF
Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced Date 03/30/17 Title Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced Download PDF
Valeant Completes Refinancing Transactions Date 03/21/17 Title Valeant Completes Refinancing Transactions Download PDF
Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018 Date 03/20/17 Title Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018 Download PDF
Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod Date 03/20/17 Title Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod Download PDF
Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses Date 03/15/17 Title Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses Download PDF
Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement Date 03/10/17 Title Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement Download PDF
Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018 Date 03/10/17 Title Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018 Download PDF
Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes Date 03/10/17 Title Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes Download PDF
Valeant Announces Launch Of Private Offering Of Senior Secured Notes Date 03/09/17 Title Valeant Announces Launch Of Private Offering Of Senior Secured Notes Download PDF
Valeant Commences Cash Tender Offer For Up To $600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018 Date 03/07/17 Title Valeant Commences Cash Tender Offer For Up To $600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018 Download PDF
Valeant Completes Approximately $1.1 Billion Pay Down Of Senior Secured Term Loans From Divestitures; To Seek Refinancing And Amendment Of Credit Agreement Date 03/06/17 Title Valeant Completes Approximately $1.1 Billion Pay Down Of Senior Secured Term Loans From Divestitures; To Seek Refinancing And Amendment Of Credit Agreement Download PDF
Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal Date 03/03/17 Title Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal Download PDF
Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation Date 03/01/17 Title Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation Download PDF
Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance Date 02/28/17 Title Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance Download pdf
Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity Date 02/27/17 Title Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity Download PDF
Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod Date 02/27/17 Title Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod Download PDF
Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products Date 02/23/17 Title Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products Download PDF
Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients Date 02/21/17 Title Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients Download PDF
Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis Date 02/16/17 Title Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis Download PDF
Valeant Pharmaceuticals To Participate At Healthcare Conferences Date 02/13/17 Title Valeant Pharmaceuticals To Participate At Healthcare Conferences Download PDF
Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance Date 01/30/17 Title Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance Download PDF
Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses Date 01/10/17 Title Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses Download PDF
Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118 Date 01/10/17 Title Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118 Download PDF
Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion Date 01/10/17 Title Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion Download PDF
Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash Date 01/09/17 Title Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash Download PDF
Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference Date 01/04/17 Title Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference Download PDF
Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors Date 01/04/17 Title Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors Download PDF